Corning Incorporated vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Corning Incorporated trades at $156.5 (market cap $131.65B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Corning Incorporated is far larger — about 5.2× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| GLW | RPRX | |
|---|---|---|
Market Cap | $131.65B | $25.27B |
Volume | 8,992,522 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $255.79 | $63.96 |
52-Week Low | $78.03 | $35.44 |
Typical Hold Time | 36 Days | 1 Days |
Enterprise Value | $138.52B | $32.50B |
Dividend Yield | 0.73% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $156.69, down 3.99% amid a bearish technical signal, though fundamentals show strong recovery with 2025 revenue reaching $15.63B and net income surging to $1.60B. The company recently secured a multi-year $3B fiber supply deal with AT&T, boosting its optical communications segment. Analyst consensus remains positive with a $171.25 price target and 57% buy ratings, but technical indicators show selling pressure with support at $149.
GLW presents a mixed outlook: the AT&T deal and earnings beat streak support growth, but high valuation ratios (P/E 70.43) and bearish technicals pose near-term risks. Investors should weigh strong cash flow projections ($1.0B net CF in 2026) against patent litigation concerns and elevated debt levels. The stock offers upside to analyst targets if execution continues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →